Chen Liao1, Zubin Yu2, Wei Guo3, Qingyun Liu4, Yanan Wu4, Yafei Li4, Li Bai1. 1. Department of Respiratory Disease, Xinqiao Hospital, Third Military Medical University, Chongqing, China. 2. Department of Thoracic Surgery, Xinqiao Hospital, Third Military Medical University, Chongqing, China. 3. Department of Systems Biology, UT MD Anderson Cancer Center, Houston, TX, USA. 4. Department of Epidemiology, College of Preventive Medicine, Third Military Medical University, Chongqing, China.
Abstract
INTRODUCTION: Inflammation has been recognized as an important contributing factor in the development and progression of lung cancer. However, the relationship between the magnitude of inflammation and prognosis in patients with lung cancer remains unclear. This meta-analysis aimed to investigate the association between levels of circulating inflammatory factors and clinical survival in patients with non-small cell lung cancer(NSCLC). METHODS: We conducted a meta-analysis of cohort studies to evaluate the prognostic effect of circulating inflammatory factors. Twenty-three studies were eligible and included in our meta-analysis. The pooled hazard ratios (HRs) and their 95% confidence intervals (CIs) were used to assess the predictive ability of circulating inflammatory factors on overall survival (OS) in patients with NSCLC. RESULTS: In overall analysis, high circulating C-reactive protein (CRP) and interleukin-6 (IL-6) level were significantly associated with shorter OS in NSCLC. However, either in CRP or IL-6 subgroup analysis by treatment, significant association with poor prognosis was observed in (radio)chemotherapy group (HR[95% CI]:1.30 [1.09-1.54] and 1.80 [1.32-2.46]; respectively), but not in surgery group. Additionally, there was no significant association between circulating IL-8, IL-10, TNF-α level and OS. CONCLUSION: Increased circulating CRP and IL-6 levels were significantly associated with poor prognosis especially in patients with unresectable NSCLC.
INTRODUCTION:Inflammation has been recognized as an important contributing factor in the development and progression of lung cancer. However, the relationship between the magnitude of inflammation and prognosis in patients with lung cancer remains unclear. This meta-analysis aimed to investigate the association between levels of circulating inflammatory factors and clinical survival in patients with non-small cell lung cancer(NSCLC). METHODS: We conducted a meta-analysis of cohort studies to evaluate the prognostic effect of circulating inflammatory factors. Twenty-three studies were eligible and included in our meta-analysis. The pooled hazard ratios (HRs) and their 95% confidence intervals (CIs) were used to assess the predictive ability of circulating inflammatory factors on overall survival (OS) in patients with NSCLC. RESULTS: In overall analysis, high circulating C-reactive protein (CRP) and interleukin-6 (IL-6) level were significantly associated with shorter OS in NSCLC. However, either in CRP or IL-6 subgroup analysis by treatment, significant association with poor prognosis was observed in (radio)chemotherapy group (HR[95% CI]:1.30 [1.09-1.54] and 1.80 [1.32-2.46]; respectively), but not in surgery group. Additionally, there was no significant association between circulating IL-8, IL-10, TNF-α level and OS. CONCLUSION: Increased circulating CRP and IL-6 levels were significantly associated with poor prognosis especially in patients with unresectable NSCLC.
Authors: Esra A Akbay; Shohei Koyama; Yan Liu; Ruben Dries; Lauren E Bufe; Michael Silkes; Md Maksudul Alam; Dillon M Magee; Robert Jones; Masahisa Jinushi; Meghana Kulkarni; Julian Carretero; Xiaoen Wang; Tiquella Warner-Hatten; Jillian D Cavanaugh; Akio Osa; Atsushi Kumanogoh; Gordon J Freeman; Mark M Awad; David C Christiani; Raphael Bueno; Peter S Hammerman; Glenn Dranoff; Kwok-Kin Wong Journal: J Thorac Oncol Date: 2017-05-06 Impact factor: 15.609
Authors: Joanna M Poczobutt; Subhajyoti De; Vinod K Yadav; Teresa T Nguyen; Howard Li; Trisha R Sippel; Mary C M Weiser-Evans; Raphael A Nemenoff Journal: J Immunol Date: 2016-02-12 Impact factor: 5.422
Authors: Dirk De Ruysscher; Jianyue Jin; Tim Lautenschlaeger; Jin-Xiong She; Zhongxing Liao; Feng-Ming Spring Kong Journal: Transl Lung Cancer Res Date: 2017-12
Authors: Jun-Chieh J Tsay; Benjamin G Wu; Imran Sulaiman; Katherine Gershner; Rosemary Schluger; Yonghua Li; Ting-An Yie; Peter Meyn; Evan Olsen; Luisannay Perez; Brendan Franca; Joseph Carpenito; Tadasu Iizumi; Mariam El-Ashmawy; Michelle Badri; James T Morton; Nan Shen; Linchen He; Gaetane Michaud; Samaan Rafeq; Jamie L Bessich; Robert L Smith; Harald Sauthoff; Kevin Felner; Ray Pillai; Anastasia-Maria Zavitsanou; Sergei B Koralov; Valeria Mezzano; Cynthia A Loomis; Andre L Moreira; William Moore; Aristotelis Tsirigos; Adriana Heguy; William N Rom; Daniel H Sterman; Harvey I Pass; Jose C Clemente; Huilin Li; Richard Bonneau; Kwok-Kin Wong; Thales Papagiannakopoulos; Leopoldo N Segal Journal: Cancer Discov Date: 2020-11-11 Impact factor: 38.272